University Of Oxford Study Supports Use Of Vaxzevria As Third Dose Against Omicron
2021-12-23
AstraZeneca’s Vaxzevria [Recombinant] significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant following a third dose booster, according to data from a new laboratory study.Neutralisation titres for Omicron were boosted following a third dose with Vaxzevria compared to titres after a second dose.The levels seen after the third dose booster were higher than the…Continue Reading